title: Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells.
abstract: Pyruvate kinase M2, an important metabolic enzyme, promotes aerobic glycolysis (Warburg effect) to facilitate cancer cell proliferation. Unravelling the status of this important glycolytic pathway enzyme under sub-lethal doses of etoposide, a commonly used anti-proliferative genotoxic drug to induce mild/moderate DNA damage in HeLa cells as a model system and discern its effect on: PKM2 expression, phosphorylation, dimer: tetramer ratio, activity and associated effects, was pertinent. Protein expression and phosphorylation of PKM2 from HeLa cells was estimated using Western blotting. Same protein lysate was also used to estimate total pyruvate kinase activity and the total dimer: tetramer content evaluated using glycerol gradient ultra-centrifugation. Intracellular PEP was estimated manually using standard curve; while NADPH was assessed by NADPH estimation kit. Unpaired t test and two-way-ANOVA was used for statistical analysis. A relative decrease in PKM2 expression and a subsequent dose and time dependent increase in Y105-phosphorylation were observed. A concomitant increase in PKM2 dimer content and Y105-phosphorylation responsible for reduced PKM2 activity promoted PEP accumulation and NADPH production, representing increased metabolic flux into PPP, a feature that favours cancer cells. It was apparent that the sub-lethal doses of etoposide induced inadequate damage to DNA in cancer cells in culture promoted pro-survival conditions due to Y105-phosphorylation of PKM2, its stable dimerization and inactivation, a unique association not known earlier, indicating what might happen in tumour revivals or recurrences.
authors.affiliation: National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India.
authors.forename: Bhupender
authors.initials: B
authors.lastname: Kumar
authors.forename: Rameshwar N K
authors.initials: RN
authors.lastname: Bamezai
mesh_terms: D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D004249:DNA Damage; D004273:DNA, Neoplasm; D005786:Gene Expression Regulation; D006367:HeLa Cells; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism*; D010427:Pentose Phosphate Pathway; D010728:Phosphoenolpyruvate / Q000378:metabolism; D010766:Phosphorylation; D055503:Protein Multimerization; D013963:Thyroid Hormones / Q000235:genetics / Q000378:metabolism*; D000097810:Thyroid Hormone-Binding Proteins
chemical_list: D002352:Carrier Proteins; D004273:DNA, Neoplasm; D008565:Membrane Proteins; D010728:Phosphoenolpyruvate; D013963:Thyroid Hormones; D000097810:Thyroid Hormone-Binding Proteins
references.citation: Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1291-6
references.pmid: 9990017
references.citation: Mol Cancer. 2013 Jul 09;12:72
references.pmid: 23837608
references.citation: Nature. 2008 Mar 13;452(7184):230-3
references.pmid: 18337823
references.citation: Mol Cell. 2015 Jan 8;57(1):95-107
references.pmid: 25482511
references.citation: Mol Cell. 2013 Nov 7;52(3):340-52
references.pmid: 24120661
references.citation: J Biol Chem. 2010 May 28;285(22):16864-73
references.pmid: 20304929
references.citation: Semin Cancer Biol. 2005 Aug;15(4):300-8
references.pmid: 15908230
references.citation: Arch Biochem Biophys. 1973 Nov;159(1):292-6
references.pmid: 4784462
references.citation: J Mol Model. 2014 Sep;20(9):2447
references.pmid: 25208557
references.citation: J Biol Chem. 2000 Jun 16;275(24):18145-52
references.pmid: 10751408
references.citation: Sci Signal. 2009 Nov 17;2(97):ra73
references.pmid: 19920251
references.citation: Curr Opin Genet Dev. 2008 Feb;18(1):54-61
references.pmid: 18387799
references.citation: FEBS Lett. 2014 Aug 19;588(16):2685-92
references.pmid: 24747424